Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients. / Becskei, Csilla; Willesen, Jakob L.; Schnyder, Manuela; Wozniakiewicz, Magda; Miroshnikova, Nataliya; Mahabir, Sean P.

I: Parasites and Vectors, Bind 13, Nr. 1, 385, 2020.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Becskei, C, Willesen, JL, Schnyder, M, Wozniakiewicz, M, Miroshnikova, N & Mahabir, SP 2020, 'Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients', Parasites and Vectors, bind 13, nr. 1, 385. https://doi.org/10.1186/s13071-020-04262-4

APA

Becskei, C., Willesen, J. L., Schnyder, M., Wozniakiewicz, M., Miroshnikova, N., & Mahabir, S. P. (2020). Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients. Parasites and Vectors, 13(1), [385]. https://doi.org/10.1186/s13071-020-04262-4

Vancouver

Becskei C, Willesen JL, Schnyder M, Wozniakiewicz M, Miroshnikova N, Mahabir SP. Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients. Parasites and Vectors. 2020;13(1). 385. https://doi.org/10.1186/s13071-020-04262-4

Author

Becskei, Csilla ; Willesen, Jakob L. ; Schnyder, Manuela ; Wozniakiewicz, Magda ; Miroshnikova, Nataliya ; Mahabir, Sean P. / Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients. I: Parasites and Vectors. 2020 ; Bind 13, Nr. 1.

Bibtex

@article{b896134b57834142ae72fdfd3a762f80,
title = "Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio{\textregistered}) for the prevention of angiostrongylosis in dogs presented as veterinary patients",
abstract = "Background: Infection with the cardiopulmonary nematode Angiostrongylus vasorum may cause severe disease in dogs, therefore prophylactic treatments are necessary to prevent infection in dogs at risk. A clinical field study was conducted to demonstrate the efficacy and safety of an oral combination of sarolaner, moxidectin and pyrantel (Simparica Trio {\textregistered} ) for the prevention of A. vasorum infection in dogs (prevention study). A survey study was conducted concurrently to determine the infection pressure in the same areas. Methods: Prevention and survey studies were both conducted at the same veterinary clinics in endemic hot spots for A. vasorum in Denmark and Italy. The prevention study was a randomized, placebo controlled, double masked study where 622 client-owned dogs were treated and tested at 30 days intervals for 10 months. In the survey study 1628 dogs that were at risk of infection and/or were suspected to be infected were tested by fecal and/or serological methods, and the percent of dogs positive for A. vasorum was calculated. Results: In the prevention study, there were no adverse events related to treatment with Simparica Trio {\textregistered} . Two placebo-treated animals became infected with A. vasorum during the 10-month study period, while none of the dogs in the combination product-treated group became infected. In the survey study, 12.2% of the study dogs were found positive to A. vasorum, indicating high exposure to the parasite during the period of the prevention study. Conclusions: Monthly oral treatment with the combination of sarolaner, moxidectin and pyrantel (Simparica Trio {\textregistered} ) was 100% effective in the prevention of natural infection with A. vasorum in dogs in highly endemic areas. In endemic areas, A. vasorum occurrence in dogs at risk is considerable.[Figure not available: see fulltext.] ",
keywords = "Angiostrongylus vasorum, French heartworm, lungworm, prevention, Simparica Trio, survey",
author = "Csilla Becskei and Willesen, {Jakob L.} and Manuela Schnyder and Magda Wozniakiewicz and Nataliya Miroshnikova and Mahabir, {Sean P.}",
year = "2020",
doi = "10.1186/s13071-020-04262-4",
language = "English",
volume = "13",
journal = "Parasites & Vectors",
issn = "1756-3305",
publisher = "BioMed Central",
number = "1",

}

RIS

TY - JOUR

T1 - Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients

AU - Becskei, Csilla

AU - Willesen, Jakob L.

AU - Schnyder, Manuela

AU - Wozniakiewicz, Magda

AU - Miroshnikova, Nataliya

AU - Mahabir, Sean P.

PY - 2020

Y1 - 2020

N2 - Background: Infection with the cardiopulmonary nematode Angiostrongylus vasorum may cause severe disease in dogs, therefore prophylactic treatments are necessary to prevent infection in dogs at risk. A clinical field study was conducted to demonstrate the efficacy and safety of an oral combination of sarolaner, moxidectin and pyrantel (Simparica Trio ® ) for the prevention of A. vasorum infection in dogs (prevention study). A survey study was conducted concurrently to determine the infection pressure in the same areas. Methods: Prevention and survey studies were both conducted at the same veterinary clinics in endemic hot spots for A. vasorum in Denmark and Italy. The prevention study was a randomized, placebo controlled, double masked study where 622 client-owned dogs were treated and tested at 30 days intervals for 10 months. In the survey study 1628 dogs that were at risk of infection and/or were suspected to be infected were tested by fecal and/or serological methods, and the percent of dogs positive for A. vasorum was calculated. Results: In the prevention study, there were no adverse events related to treatment with Simparica Trio ® . Two placebo-treated animals became infected with A. vasorum during the 10-month study period, while none of the dogs in the combination product-treated group became infected. In the survey study, 12.2% of the study dogs were found positive to A. vasorum, indicating high exposure to the parasite during the period of the prevention study. Conclusions: Monthly oral treatment with the combination of sarolaner, moxidectin and pyrantel (Simparica Trio ® ) was 100% effective in the prevention of natural infection with A. vasorum in dogs in highly endemic areas. In endemic areas, A. vasorum occurrence in dogs at risk is considerable.[Figure not available: see fulltext.]

AB - Background: Infection with the cardiopulmonary nematode Angiostrongylus vasorum may cause severe disease in dogs, therefore prophylactic treatments are necessary to prevent infection in dogs at risk. A clinical field study was conducted to demonstrate the efficacy and safety of an oral combination of sarolaner, moxidectin and pyrantel (Simparica Trio ® ) for the prevention of A. vasorum infection in dogs (prevention study). A survey study was conducted concurrently to determine the infection pressure in the same areas. Methods: Prevention and survey studies were both conducted at the same veterinary clinics in endemic hot spots for A. vasorum in Denmark and Italy. The prevention study was a randomized, placebo controlled, double masked study where 622 client-owned dogs were treated and tested at 30 days intervals for 10 months. In the survey study 1628 dogs that were at risk of infection and/or were suspected to be infected were tested by fecal and/or serological methods, and the percent of dogs positive for A. vasorum was calculated. Results: In the prevention study, there were no adverse events related to treatment with Simparica Trio ® . Two placebo-treated animals became infected with A. vasorum during the 10-month study period, while none of the dogs in the combination product-treated group became infected. In the survey study, 12.2% of the study dogs were found positive to A. vasorum, indicating high exposure to the parasite during the period of the prevention study. Conclusions: Monthly oral treatment with the combination of sarolaner, moxidectin and pyrantel (Simparica Trio ® ) was 100% effective in the prevention of natural infection with A. vasorum in dogs in highly endemic areas. In endemic areas, A. vasorum occurrence in dogs at risk is considerable.[Figure not available: see fulltext.]

KW - Angiostrongylus vasorum

KW - French heartworm

KW - lungworm

KW - prevention

KW - Simparica Trio

KW - survey

U2 - 10.1186/s13071-020-04262-4

DO - 10.1186/s13071-020-04262-4

M3 - Journal article

C2 - 32727548

AN - SCOPUS:85088850810

VL - 13

JO - Parasites & Vectors

JF - Parasites & Vectors

SN - 1756-3305

IS - 1

M1 - 385

ER -

ID: 247501452